Key takeaways
Duobrii (halobetasol/tazarotene) and Cosentyx (secukinumab) are both medications used to treat plaque psoriasis, but they belong to different medication classes and have distinct characteristics. Duobrii is a topical lotion that combines a corticosteroid (halobetasol) and a retinoid (tazarotene) to reduce inflammation and thin psoriasis plaques. It is applied once daily to the skin. Cosentyx, on the other hand, is an injectable interleukin 17 (IL-17) inhibitor that lowers swelling, pain, and inflammation. Both medications are only available in a branded version. Both medications are not usually recommended during pregnancy. Common side effects of Duobrii include skin rash and application site pain, whereas Cosentyx may cause cold symptoms and diarrhea. Additionally, Cosentyx is approved for a wider range of conditions, including psoriatic arthritis and ankylosing spondylitis, unlike Duobrii, which is specifically for plaque psoriasis.
